drugset / Trial / NCT06669611
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
We expect to conduct a clinical trial in recurrent and metastatic nasopharyngeal carcinoma patients to explore and compare the efficacy and safety of induction chemotherapy (TPC vs. GP) with combination therapy of Camrelizumab.
Timeline
- Start
- 2024-11-27
- Primary completion
- 2027-11-20
- Completion
- 2029-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Comparator | Cisplatin | Other / unclassified | 60 mg/m2 | — |
| Comparator | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Comparator | Gemcitabine | Small molecule | 1 g | — |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | — |
| Comparator | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |